Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-APZ2-CVU for Chronic Venous Ulcer
NCT03257098Phase 2Completed
- Sponsor
- RHEACELL
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EBESANAR in venous ulcer, sponsored by RHEACELL. Primary endpoints: Percentage of wound size reduction at Week 12 and Assessment of adverse event (AE) occurrence up to 12 months. Started Nov 2017; status: completed.
02
Drugs
EBESANAR
03
Conditions
venous ulcer
Beyond the preview
Go deeper on NCT03257098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257098.